Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene Starts Second China Pivotal Phase II Trial of PD-1 Drug

publication date: Jul 5, 2017
BeiGene, a Beijing oncology company, has started the second pivotal China Phase II trial of its PD-1 immuno-oncology drug, BGB-A317, in patients with bladder cancer. The first pivotal trial is testing BGB-A317 in patients with Hodgkin lymphoma. Last week, BeiGene announced positive preliminary data from a Phase I trial of the candidate in patients with advanced liver cancer. In the trial, BGB-A317 was generally well-tolerated and showed signs of efficacy in the heavily pre-treated patients. The news sent BeiGene's stock 21% higher to $54.46, an all-time high. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital